UY36574A - BROMODOMINIUM INHIBITORS - Google Patents

BROMODOMINIUM INHIBITORS

Info

Publication number
UY36574A
UY36574A UY0001036574A UY36574A UY36574A UY 36574 A UY36574 A UY 36574A UY 0001036574 A UY0001036574 A UY 0001036574A UY 36574 A UY36574 A UY 36574A UY 36574 A UY36574 A UY 36574A
Authority
UY
Uruguay
Prior art keywords
bromodominium
inhibitors
compound
formula
salts
Prior art date
Application number
UY0001036574A
Other languages
Spanish (es)
Inventor
Philip G Humphreys
Christopher Roland Wellaway
John Alexander Brown
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY36574A publication Critical patent/UY36574A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención va destinada al compuesto de formula (I), que es 5-[1-(1,3- dimetoxipropan-2-il)-5-(morfolin-4-il)-1H-1,3-benzodiazol-2-il]-1,3-dimetil-1,2-dihidropiridin-2-ona:o una de sus sales, en particular una de sus sales farmacéuticamente aceptable. El compuesto de fórmula (I) se ha identificado como inhibidor de BET y, de este modo, tiene un potencial para su uso en terapia, por ejemplo, en el tratamiento de enfermedades inflamatorias y/o autoinmunitarias, tales como artritis reumatoide; y cánceres.The present invention is directed to the compound of formula (I), which is 5- [1- (1,3-dimethoxypropan-2-yl) -5- (morpholin-4-yl) -1H-1,3-benzodiazole- 2-yl] -1,3-dimethyl-1,2-dihydropyridin-2-one: or one of its salts, in particular one of its pharmaceutically acceptable salts. The compound of formula (I) has been identified as a BET inhibitor and thus has a potential for use in therapy, for example, in the treatment of inflammatory and / or autoimmune diseases, such as rheumatoid arthritis; and cancers

UY0001036574A 2015-03-05 2016-03-03 BROMODOMINIUM INHIBITORS UY36574A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201503720A GB201503720D0 (en) 2015-03-05 2015-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
UY36574A true UY36574A (en) 2016-09-30

Family

ID=52998420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036574A UY36574A (en) 2015-03-05 2016-03-03 BROMODOMINIUM INHIBITORS

Country Status (5)

Country Link
AR (1) AR103844A1 (en)
GB (1) GB201503720D0 (en)
TW (1) TW201704230A (en)
UY (1) UY36574A (en)
WO (1) WO2016139292A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX2018001751A (en) 2015-08-11 2018-08-01 Neomed Inst Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals.
KR20180039669A (en) 2015-08-12 2018-04-18 네오메드 인스티튜트 Substituted benzimidazoles, methods for their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN109280046B (en) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 Benzimidazole derivative, preparation method thereof and application thereof in medicine
CN109384784B (en) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 Sulfonamide derivative, preparation method thereof and application thereof in medicine
CA3137870A1 (en) * 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (en) 2005-12-12 2008-01-30 Glaxo Group Ltd COLLECTOR TO BE USED IN MEDICINAL DISPENSER
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones

Also Published As

Publication number Publication date
TW201704230A (en) 2017-02-01
WO2016139292A1 (en) 2016-09-09
GB201503720D0 (en) 2015-04-22
AR103844A1 (en) 2017-06-07

Similar Documents

Publication Publication Date Title
UY36574A (en) BROMODOMINIUM INHIBITORS
CL2016001889A1 (en) (2s) -n - [(1s) -1-cyano-2-phenylethyl] -1,4-oxazepan-2-carboxamides as dipeptidyl peptidase 1 inhibitors.
CY1120635T1 (en) AMINOETERALYL BENZAMIDS AS KINASE INhibitors
CL2020001218A1 (en) Useful compounds to inhibit cdk7.
SV2018005663A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
CR20150633A (en) BIPIRAZOL DERIVATIVES AS JAK INHIBITORS
CU20160167A7 (en) COMPOUNDS OF PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS USEFUL IN THE TREATMENT OF ALLERGIC AND RESPIRATORY CONDITIONS
CU20170015A7 (en) COMPOSITE OF (PIRAZOLILAMINO) PYRIMIDINYL BIKE (3.2.1) OCT-8-IL
UY35898A (en) ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?.
EA201691625A1 (en) AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY COMPOUNDS
NI201600018A (en) PYRROLAMIDE DERIVATIVES SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B.
ECSP20035222A (en) AMINO-FLUOROPIPERIDINE DERIVATIVE AS A KINASE INHIBITOR
SV2018005680A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
CU24411B1 (en) COMPOSITE DERIVED FROM BENZAMIDE REPLACED WITH 1,3-TIAZOL-2-ILO USEFUL FOR THE TREATMENT OF NEUROGENIC DISORDERS
BR112018003026A2 (en) compositions comprising a pi3k inhibitor and an hdac inhibitor
CU20160111A7 (en) BICYCLIC HETEROCICLYL COMPOUNDS AS IRAK4 INHIBITORS
CU20160188A7 (en) INDAZOLE COMPOUNDS SUBSTITUTED AS IRAK4 INHIBITORS
UY35617A (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
ECSP20035588A (en) DERIVATIVE OF AMINO-METHYL PIPERIDINE AS A KINASE INHIBITOR
CO6870032A2 (en) New phosphodiesterase type 10a inhibitor compounds
DOP2015000270A (en) POTENTIAL OF INHIBITORS OF THE HOMOLOGIST OF ZESTE
GT201400089A (en) NEW INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODIESTERASE
UY36153A (en) 3-QUINASA DELTA PHOSFOINOSYTI INHIBITORS FOR USE IN THE TREATMENT OF AN IMMUNOAMPOLLOSUS CUTANEOUS DISEASE MEDIATED BY AUTOANTIBODIES?
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CL2020001752A1 (en) Derivative of oxy-fluoropiperidine as a kinase inhibitor.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104